Edition:
India

Indivior PLC (INDV.L)

INDV.L on London Stock Exchange

46.91GBp
5:20pm IST
Change (% chg)

-1.65 (-3.40%)
Prev Close
48.56
Open
48.14
Day's High
48.93
Day's Low
46.00
Volume
1,180,208
Avg. Vol
5,856,400
52-wk High
504.60
52-wk Low
20.98

Latest Key Developments (Source: Significant Developments)

Drugmaker Indivior Sees 2019 Revenue Between $525 Mln And $575 Mln
Thursday, 2 May 2019 

May 2 (Reuters) - Indivior PLC ::INDIVIOR PLC - 1ST QUARTER RESULTS.INDIVIOR PLC - SUBLOCADE™ PERFORMANCE ON TRACK.INDIVIOR PLC - QTRLY NET REVENUE OF $238M DECLINED 6% (5% AT CONSTANT CURRENCY).INDIVIOR PLC QTRLY NET INCOME WAS $66M (Q1 2018: $93M).INDIVIOR PLC - Q1 2019 RESULTS AND FY 2019 GUIDANCE ANNOUNCED.INDIVIOR PLC - ON AN ADJUSTED BASIS, QTRLY NET INCOME INCREASED 14% TO $89M.INDIVIOR PLC - QTRLY U.S. BUPRENORPHINE MARKET GROWTH CONTINUED AT LOW DOUBLE-DIGIT LEVELS.INDIVIOR PLC - SEES FY NET REVENUE IS EXPECTED TO BE IN RANGE OF $525M TO $575M.INDIVIOR PLC - QTRLY SUBOXONE FILM MARKET SHARE AVERAGED 48% AND EXITED AT 40%.INDIVIOR PLC - SEES FY NET (LOSS) / INCOME RANGE OF APPROXIMATELY ($40M) TO $10M (EXCLUDING EXCEPTIONAL ITEMS AND AT CONSTANT EXCHANGE RATES).INDIVIOR - FY NET REVENUE GUIDANCE ASSUMES SHARE EROSION OF SUBOXONE FILM, AUTHORIZED GENERIC FILM PRODUCT AT RATES OF OBSERVED ANALOGUES FOR REST OF 2019.INDIVIOR PLC - PREVIOUSLY-STATED GUIDANCE ELEMENTS MAINTAINED, NAMELY SUBLOCADE NET REVENUE OF BETWEEN $50M-$70M IN FY.INDIVIOR PLC - IN ADVANCED DISCUSSIONS WITH DEPARTMENT OF JUSTICE (DOJ) ABOUT A POSSIBLE RESOLUTION TO ITS INVESTIGATION UNTIL RECENTLY.INDIVIOR PLC - RESPONDED TO U.S. ATTORNEY'S OFFICE SUBPOENAS AND COOPERATED FULLY WITH DEPARTMENT AND PROSECUTORS.INDIVIOR PLC - GROUP WAS IN ADVANCED DISCUSSIONS WITH DEPARTMENT OF JUSTICE (DOJ) ABOUT A POSSIBLE RESOLUTION TO ITS INVESTIGATION UNTIL RECENTLY.  Full Article

Newtyn Management Discloses 3.06 Pct Stake In Indivior - Filing
Thursday, 2 May 2019 

May 2 (Reuters) - Indivior PLC ::NEWTYN MANAGEMENT DISCLOSES 3.06 PERCENT STAKE IN INDIVIOR PLC - FILING.  Full Article

Reckitt Benckiser Sees Improving Growth In Remainder Of Year After Slow Q1
Thursday, 2 May 2019 

May 2 (Reuters) - Reckitt Benckiser Group PLC ::Q1 TOTAL SALES 3,157 MILLION STG VERSUS 3,111 MILLION STG AS REPORTED A YEAR EARLIER.RB2.0 REMAINS ON TRACK..REMAIN ON TRACK FOR FULL YEAR NET REVENUE TARGET OF +3-4% LFL WITH GROWTH TO BE H2 WEIGHTED..EXPECT TO SEE IMPROVING GROWTH IN REMAINDER OF YEAR, PARTICULARLY IN H2.REITERATE 2019 TARGETS OF +3-4% LFL NET REVENUE GROWTH AND ADJUSTED(1) OPERATING MARGIN TO BE MAINTAINED.RECKITT BENCKISER, ON INDIVIOR/RB PHARMA-RELATED MATTERS, SAYS REMAINS INVOLVED IN ONGOING INVESTIGATIONS BY US DOJ, US FEDERAL TRADE COMMISSION.MAY INCUR LIABILITIES IN RELATION TO MATTERS RELATING TO INDIVIOR / RB PHARMA-RELATED LITIGATION MATTERS.ONGOING INVESTIGATIONS REFERS TO MATTERS RELATING TO RB PHARMACEUTICALS BUSINESS PRIOR TO ITS DEMERGER IN DECEMBER 2014 TO FORM INDIVIOR.FINAL COST ON RESOLVING INDIVIOR / RB PHARMA-RELATED LITIGATION MATTERS MAY BE SUBSTANTIALLY HIGHER THAN THIS PROVISION.  Full Article

Reckitt Says U.S. DoJ's Indictment Of Indivior Not Against Co
Wednesday, 10 Apr 2019 

April 10 (Reuters) - Reckitt Benckiser Group PLC ::US JUSTICE DEPARTMENT INDICTMENT OF INDIVIOR PLC.NOTES 9 APRIL 2019 INDICTMENT BY US JUSTICE DEPARTMENT IN RELATION TO INDIVIOR PLC AND INDIVIOR INC.INDICTMENT NOT AGAINST CO OR ANY GROUP COMPANY AND CURRENTLY HAVE NO ADDITIONAL OR NEW INFORMATION IN RESPECT OF THE MATTER.REFERS INVESTORS TO STATEMENTS INCLUDING NOTE IN 2018 ANNUAL REPORT IN WHICH CO STATED THAT AT DEC 31, IT WAS RECOGNISING PROVISION OF $400M.  Full Article

Entities Affiliated To Standard Life Aberdeen Disclose 17.31 Pct Stake In Indivior As Of Feb. 28
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Indivior PLC ::ENTITIES AFFILIATED TO STANDARD LIFE ABERDEEN DISCLOSE 17.31 PERCENT STAKE IN INDIVIOR AS OF FEB. 28 VERSUS PRIOR STAKE OF 16.04 PERCENT.  Full Article

Scopia Management Cuts Stake To 15.98 Pct From 16.94 Pct In Indivior - Filing
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - Indivior PLC ::SCOPIA MANAGEMENT CUTS STAKE TO 15.98% FROM 16.94% IN INDIVIOR PLC - FILING.  Full Article

Indivior Launches Generic Version Of Its Suboxone Film
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - Indivior PLC ::INDIVIOR LAUNCHES SUBOXONE FILM AUTHORIZED GENERIC.U.S. AFFILIATE, INDIVIOR INC HAS LAUNCHED AN AUTHORIZED GENERIC VERSION OF SUBOXONE FILM (CIII) IN U.S.AUTHORIZED GENERIC IS BEING MARKETED AND DISTRIBUTED ON INDIVIOR'S BEHALF BY SANDOZ INC.DECISION TO LAUNCH SUBOXONE GENERIC BASED ON MARKET IMPACT EXPECTED FROM ANTICIPATED "AT RISK" LAUNCH OF GENERIC DR. REDDY'S AND/OR ALVOGEN.  Full Article

Indivior Says The Lancet Publishes Phase 3 Results Of SUBLOCADE
Tuesday, 19 Feb 2019 

Feb 19 (Reuters) - Indivior PLC ::THE LANCET PUBLISHES PHASE 3 RESULTS OF SUBLOCADET.DATA FROM PIVOTAL PHASE 3 CLINICAL TRIAL EVALUATING SUBLOCADE INJECTION FOR SUBCUTANEOUS USE WERE PUBLISHED BY LANCET.24-WEEK TRIAL MET ITS PRIMARY AND KEY SECONDARY ENDPOINTS FOR BOTH 300/300 MG AND 300/100 MG DOSAGE REGIMENS OF SUBLOCADE.STUDY DEMONSTRATED CLINICALLY AND STATISTICALLY SIGNIFICANT DIFFERENCES IN PERCENTAGE ABSTINENCE FROM OPIOID USE COMPARED TO PLACEBO.  Full Article

Indivior Says Court Denied Its Motion To Prevent Sale Of Suboxone Copycats
Tuesday, 12 Feb 2019 

Feb 12 (Reuters) - Indivior PLC ::FEDERAL COURT DENIES MOTION TO STAY.COURT OF APPEALS FOR FEDERAL CIRCUIT DENIES MOTION TO STAY ISSUANCE OF MANDATE.FILED EMERGENCY MOTION TO STAY MANDATE PENDING RESOLUTION OF ITS FORTHCOMING APPLICATION FOR AN ADMINISTRATIVE STAY TO SUPREME COURT OF US.AFTER MANDATE ISSUES, REDDY'S, ALVOGEN WILL NO LONGER BE PREVENTED FROM SELLING OR IMPORTING GENERIC BUPRENORPHINE/NALOXONE SUBLINGUAL FILM.COURT DENIED CO'S MOTION TO STAY ISSUANCE OF MANDATE FOLLOWING CAFC'S RULING VACATING PRELIMINARY INJUNCTION AGAINST DR. REDDY'S.  Full Article

U.S. Court Denies Indivior motion relating to preliminary injunction against Dr. Reddy's
Tuesday, 5 Feb 2019 

Feb 5 (Reuters) - Indivior PLC ::INDIVIOR RESPONDS TO CAFC REHEARING DECISION.COURT OF APPEALS FOR FEDERAL CIRCUIT DENIES MOTION FOR REHEARING OR REHEARING EN BANC.TO FILE EMERGENCY MOTION WITH CAFC TO STAY ISSUANCE OF MANDATE PENDING RESOLUTION OF APPEAL OF DECISION FINDING REDDY'S DOES NOT INFRINGE U.S. PATENT.AS A RESULT OF COST INITIATIVES, FY 2019 OPERATING EXPENSE BASE (SG&A AND RESEARCH AND DEVELOPMENT) IS EXPECTED TO BE REDUCED TO $440M TO $460M.CO "FACES MAJOR DISRUPTION" IN IMMEDIATE FUTURE FROM POTENTIAL MATERIAL AND RAPID LOSS OF MARKET SHARE OF SUBOXONE FILM PRODUCT.ASSUMES THAT DRL WILL RESUME LAUNCH OF ITS GENERIC BUPRENORPHINE/NALOXONE SUBLINGUAL FILM PRODUCT IN U.S. ONCE CAFC ISSUES MANDATE.  Full Article

Indivior signs deal to sell schizophrenia drug in Canada

British drugmaker Indivior Plc on Thursday signed a licensing agreement with HLS Therapeutics Inc for the sale of its schizophrenia drug Perseris in Canada.